All Outputs (186)

Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression (2022)
Journal Article
Bradley, C. R., Cox, E. F., Palaniyappan, N., Aithal, G. P., Francis, S. T., & Guha, I. N. (2022). Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression. European Radiology Experimental, 6(1), 52. https://doi.org/10.1186/s41747-022-00303-y

Abstract: Background: We annually monitored stable compensated cirrhosis (CC) patients to evaluate serial variation in blood serum, liver stiffness, and multiparametric magnetic resonance imaging (mpMRI) measures to provide reference change values (R... Read More about Variability of noninvasive MRI and biological markers in compensated cirrhosis: insights for assessing disease progression.

Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review (2022)
Journal Article
Niu, H., Atallah, E., Alvarez-Alvarez, I., Medina-Caliz, I., Aithal, G. P., Arikan, C., Andrade, R. J., & Lucena, M. I. (2022). Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review. Drug Safety, 45, 1329-1348. https://doi.org/10.1007/s40264-022-01224-w

Introduction
Drug-induced liver injury (DILI) is a rare but serious adverse event that can progress to acute liver failure (ALF). The evidence for treatment of DILI in children is scarce.

Objective
We aimed to comprehensively review the availabl... Read More about Therapeutic Management of Idiosyncratic Drug-Induced Liver Injury and Acetaminophen Hepatotoxicity in the Paediatric Population: A Systematic Review.

A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry (2022)
Journal Article
Björnsson, E. S., Stephens, C., Atallah, E., Alvarez-Alvarez, I., Robles-Diaz, M., Gerbes, A., Weber, S., Stirnimann, G., Kullak-Ublick, G., Cortez-Pinto, H., Grove, J. I., Lucena, M. I., Andrade, R. J., & Aithal, G. P. (2022). A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry. Liver International, 43(1), 115-126. https://doi.org/10.1111/liv.15378

Background & Aims: No multi-national prospective study of drug-induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short-term outcomes of the cases and controls is reported.... Read More about A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry.

Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study (2022)
Journal Article
Vijay, A., Al-Awadi, A., Chalmers, J., Balakumaran, L., Grove, J. I., Valdes, A. M., Taylor, M. A., Shenoy, K. T., & Aithal, G. P. (2022). Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study. Nutrients, 14(14), 2808. https://doi.org/10.3390/nu14142808

Background: Non-alcoholic fatty liver disease (NAFLD) is a global problem growing in parallel to the epidemics of obesity and diabetes, with South Asians being particularly susceptible. Nutrition and behaviour are important modifiers of the disease,... Read More about Development of Food Group Tree-Based Analysis and Its Association with Non-Alcoholic Fatty Liver Disease (NAFLD) and Co-Morbidities in a South Indian Population: A Large Case-Control Study.

Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis (2022)
Journal Article
Cianci, N., Subhani, M., Hill, T., Khanna, A., Zheng, D., Sheth, A., Crooks, C., & Aithal, G. P. (2022). Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis. World Journal of Hepatology, 14(5), 1025-1037. https://doi.org/10.4254/wjh.v14.i5.1025

BACKGROUND Non-alcoholic fatty liver disease (NAFLD) represents a growing public health concern, with patients having higher risk of morbidity and mortality. It has a considerably high prevalence in the general population, estimated 20%-40% in Europe... Read More about Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis.

Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis (2022)
Journal Article
Subhani, M., Sheth, A., Ahmed, J., Wijayasiri, P., Gardezi, S. A., Enki, D., Morling, J. R., Aithal, G. P., Ryder, S. D., & Aravinthan, A. D. (2022). Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis. Thrombosis Research, 215, 19-29. https://doi.org/10.1016/j.thromres.2022.05.004

Background and Aims: Historically, bleeding was thought to be a frequent and fatal complication of liver disease. However, thrombosis due to coagulation disorders in cirrhosis remains a real risk. We aim to systematically analyse published articles t... Read More about Incidence and prevalence of venous thromboembolism in chronic liver disease: A systematic review and meta-analysis.

Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum (2022)
Journal Article
Nakafero, G., Grainge, M. J., Card, T., Mallen, C. D., Riley, R., Van Der Windt, D., Fox, C. P., Taal, M. W., Aithal, G. P., Williams, H. C., & Abhishek, A. (2022). Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum. Rheumatology Advances in Practice, 6(2), rkac046. https://doi.org/10.1093/rap/rkac046

Objective: The aim was to examine the incidence and pattern of MMF discontinuation associated with abnormal monitoring blood-test results. Methods: Data from people prescribed MMF for common inflammatory conditions in the Clinical Practice Research D... Read More about Incidence and pattern of mycophenolate discontinuation associated with abnormal monitoring blood-test results: cohort study using data from the Clinical Practice Research Datalink Aurum.

Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis (2022)
Journal Article
Subhani, M., Talat, U., Knight, H., Morling, J. R., Jones, K. A., Aithal, G. P., Ryder, S. D., Llewellyn-Beardsley, J., & Rennick-Egglestone, S. (2022). Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis. PLoS ONE, 17(5), e0268034. https://doi.org/10.1371/journal.pone.0268034

Background and aims Narratives of recovery from alcohol misuse have been analysed in a range of research studies. This paper aims to produce a conceptual framework describing the characteristics of alcohol misuse recovery narratives that are in the r... Read More about Characteristics of alcohol recovery narratives: Systematic review and narrative synthesis.

Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial (2022)
Journal Article
Wang, J. B., Huang, A., Wang, Y., Ji, D., Liang, Q. S., Zhao, J., Zhou, G., Liu, S., Niu, M., Sun, Y., Tian, H., Teng, G. J., Chang, B. X., Bi, J. F., Peng, X. X., Xin, S., Xie, H., Ma, X., Mao, Y. M., …Zou, Z. (2022). Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial. Alimentary Pharmacology and Therapeutics, 55(10), 1297-1310. https://doi.org/10.1111/apt.16902

Background
Treatment of chronic drug-induced liver injury (DILI) or herb-induced liver injury(HILI) is an important and unresolved challenge. There is no consensus regarding the indications for corticosteroids for chronic DILI/HILI.

Aims
To inve... Read More about Corticosteroid plus glycyrrhizin therapy for chronic drug‐ or herb‐induced liver injury achieves biochemical and histological improvements: a randomised open‐label trial.

A revised electronic version of RUCAM for the diagnosis of DILI (2022)
Journal Article
Hayashi, P. H., Lucena, M. I., Fontana, R. J., Bjornsson, E. S., Aithal, G. P., Barnhart, H., Gonzalez Jimenez, A., Yang, Q., Gu, J., Andrade, R. J., & Hoofnagle, J. H. (2022). A revised electronic version of RUCAM for the diagnosis of DILI [A Revised Electronic Version of RUCAM for the Diagnosis of Drug Induced Liver Injury]. Hepatology, 76(1), 18-31. https://doi.org/10.1002/hep.32327

Background and Aims: Roussel Uclaf Causality Assessment Method (RUCAM) for DILI has been hindered by subjectivity and poor reliability. We sought to improve the RUCAM using data from the Drug-Induced Liver Injury Network (DILIN) and the Spanish DILI... Read More about A revised electronic version of RUCAM for the diagnosis of DILI.

HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19 (2022)
Journal Article
Astbury, S., Reynolds, C. J., Butler, D. K., Munoz-Sandoval, D. C., Lin, K.-M., Pieper, F. P., Otter, A., Kouraki, A., Cusin, L., Nightingale, J., Vijay, A., Craxford, S., Aithal, G. P., Tighe, P. J., Gibbons, J. M., Pade, C., Joy, G., Maini, M., Chain, B., …Altmann, D. M. (2022). HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19. Immunology, 166(1), 68-77. https://doi.org/10.1111/imm.13450

SARS-CoV-2 infection results in different outcomes ranging from asymptomatic infection to mild or severe disease and death. Reasons for this diversity of outcome include differences in challenge dose, age, gender, comorbidity and host genomic variati... Read More about HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.

Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres (2022)
Journal Article
Gordon, V., Adhikary, R., Appleby, V., Das, D., Day, J., Delahooke, T., Dixon, S., Elphick, D., Hardie, C., Heneghan, M. A., Hoeroldt, B., Hooper, P., Hutchinson, J., Jones, R., Khan, F., Aithal, G. P., Metcalf, J., Nkhoma, A., Pelitari, S., …Gleeson, D. (2022). Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres. Liver International, 42(7), 1571-1584. https://doi.org/10.1111/liv.15241

Background
With few data regarding treatment and outcome of patients with AIH outside of large centres we present such a study of patients with AIH in 28 UK hospitals of varying size and facilities.

Methods
Patients with AIH were identified in 1... Read More about Treatment and Outcome of Autoimmune Hepatitis (AIH): Audit of 28 UK centres.

Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients (2022)
Journal Article
Liu, K., Yip, T. C. F., Masson, S., Fateen, W., Schwantes‐An, T., McCaughan, G. W., Morgan, T. R., Aithal, G. P., & Seth, D. (2022). Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients. Liver Cancer International, 3(2), 99-104. https://doi.org/10.1002/lci2.47

Background and Aims
The aMAP score was recently devised to predict hepatocellular carcinoma (HCC) development. However, its performance was not tested in alcohol-related cirrhosis (ALC). We aimed to validate the aMAP score in a cohort of ALC patient... Read More about Validation of the aMAP score to predict hepatocellular carcinoma development in a cohort of alcohol‐related cirrhosis patients.

Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial (2022)
Journal Article
Arndtz, K., Chen, Y.-Y., Rowe, A., Homer, V., Kirkham, A., Douglas-Pugh, J., Slade, D., Thorburn, D., Barnes, E., Aithal, G., Newsome, P., Smith, D., Adams, D., Weston, C., & Hirschfield, G. (2022). Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial. Efficacy and Mechanism Evaluation, 9(1), 1-54. https://doi.org/10.3310/zpnf4670

Background: Primary sclerosing cholangitis is a progressive and fibrotic liver disease. Treatments remain inadequate, and patients with persistent elevations in activity of alkaline phosphatase are at greatest risk of disease progression. Studies in... Read More about Monoclonal antibody BTT1023 targeting vascular adhesion protein 1 for treating primary sclerosing cholangitis: BUTEO single-arm Phase II trial.

Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour? (2022)
Journal Article
Subhani, M., Harman, D. J., Scott, R. A., Bennett, L., Wilkes, E. A., James, M. W., Aithal, G. P., Ryder, S. D., & Guha, I. N. (2022). Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?. Biomedicines, 10(2), 477. https://doi.org/10.3390/biomedicines10020477

Introduction: Alcohol is the leading cause of cirrhosis in Western populations. The early identification of high-risk drinkers followed by intervention is an effective way to reduce harm. We aim to assess the feasibility of integrating transient elas... Read More about Transient Elastography in Community Alcohol Services: Can It Detect Significant Liver Disease and Impact Drinking Behaviour?.

Integrins as a drug target in liver fibrosis (2022)
Journal Article
Rahman, S. R., Roper, J. A., Grove, J. I., Aithal, G. P., Pun, K. T., & Bennett, A. J. (2022). Integrins as a drug target in liver fibrosis. Liver International, 42(3), 507-521. https://doi.org/10.1111/liv.15157

As the worldwide prevalence of chronic liver diseases is high and continuing to increase, there is an urgent need for treatment to prevent cirrhosis-related morbidity and mortality. Integrins are heterodimeric cell-surface proteins that are promising... Read More about Integrins as a drug target in liver fibrosis.

Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease (2021)
Journal Article
Govaere, O., Kragh Petersen, S., Martinez-Lopez, N., Wouters, J., Van Haele, M., Mancina, R. M., Jamialahmadi, O., Bilkei-Gorzo, O., Bel Lassen, P., Darlay, R., Peltier, J., Palmer, J. M., Younes, R., Tiniakos, D., Aithal, G. P., Allison, M., Vacca, M., Göransson, M., Berlinguer-Palmini, R., …Härtlova, A. (2022). Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 76(5), 1001-1012. https://doi.org/10.1016/j.jhep.2021.12.012

Background & Aims: Obesity-associated inflammation is a key player in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). However, the role of macrophage scavenger receptor 1 (MSR1, CD204) remains incompletely understood.

Methods: 170... Read More about Macrophage Scavenger Receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease.

Speaking of the (Barely legal) elephant in the room: Herbal or dietary supplement related acute liver failure (2021)
Journal Article
Aithal, G. P. (2022). Speaking of the (Barely legal) elephant in the room: Herbal or dietary supplement related acute liver failure. Liver Transplantation, 28(2), 159-160. https://doi.org/10.1002/lt.26377

Titled ‘Barely legal’, Banksy’s first United States (USA) exhibition showcased Tai, an Indian elephant, painted with pink and gold pattern to blend in with the wallpaper of the living room, intended to mock the art world’s claim for the true portraya... Read More about Speaking of the (Barely legal) elephant in the room: Herbal or dietary supplement related acute liver failure.

Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease (2021)
Journal Article
Mak, A. L., Lee, J., van Dijk, A.-M., Vali, Y., Aithal, G. P., Schattenberg, J. M., Anstee, Q. M., Brosnan, M. J., Zafarmand, M. H., Ramsoekh, D., Harrison, S. A., Nieuwdorp, M., Bossuyt, P. M., & Holleboom, A. G. (2021). Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines, 9(12), 1920. https://doi.org/10.3390/biomedicines9121920

The prevalence and severity of non-alcoholic fatty liver disease (NAFLD) is increasing, yet adequately validated tests for care paths are limited and non-invasive markers of disease progression are urgently needed. The aim of this work was to summari... Read More about Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease.

Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study (2021)
Journal Article
Hashim, A., Bremner, S., Grove, J., Astbury, S., Mengozzi, M., O’Sullivan, M., Macken, L., Worthley, T., Katarey, D., Aithal, G., & Verma, S. (2022). Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study. Liver International, 42(3), 628-639. https://doi.org/10.1111/liv.15122

Background/aims: Community-based assessment and management of chronic liver disease (CLD) in people who are homeless (PWAH) remains poorly described. We aimed to determine prevalence/predictors of chronic liver disease (CLD) in PWAH and assess perfor... Read More about Chronic liver disease in homeless individuals and performance of non‐invasive liver fibrosis and injury markers: VALID study.